Drug Profile

DSP 106 - KAHR Medical

Alternative Names: DSP-106; KAHR-106; PD-L1/CD70 fusion protein - KAHR Medical

Latest Information Update: 28 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator KAHR Medical
Class Antineoplastics; Proteins
Mechanism of Action CD27 antigen stimulants; CD70 antigen modulators; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2022 No recent reports of development identified for preclinical development in Cancer in Israel (Parenteral)
11 Apr 2018 Preclinical trials in Cancer in Israel (Parenteral) (KAHR Medical pipeline, April 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com